CAH Stock Recent News
CAH LATEST HEADLINES
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DUBLIN, Ohio , July 11, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the launch of the Cardinal Health™ One Voice Initiative for pharmacy advocacy, which provides direct financial assistance to state pharmacy associations for the purpose of supporting independent pharmacists' advocacy efforts. This investment furthers Cardinal Health's longstanding advocacy around the future of independent pharmacies and ongoing partnerships with industry organizations to support pharmacists' efforts to build relationships with elected officials at all levels of government.
In the closing of the recent trading day, Cardinal Health (CAH) stood at $162.17, denoting a -1.27% move from the preceding trading day.
In the closing of the recent trading day, Cardinal Health (CAH) stood at $164.93, denoting a +1.82% move from the preceding trading day.
In the most recent trading session, Cardinal Health (CAH) closed at $161.98, indicating a -1.47% shift from the previous trading day.
Dividend stocks are a favorite among investors for good reason.
Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Brokers are bullish on CBRL, BGSF, ARCB, CAH and AN as improving estimates and value metrics signal strength for 2H25.
Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising payouts in 2025 and an average growth rate of 4.86%. I identified 21 Aristocrats as both potentially undervalued and offering a projected long-term annualized return of at least 10%.